Clinical Risk Grouping Solutions Comprehensive Study by Type (Scorecard and Visualization Tools, Dashboard Analysis, Risk Report), End Users (Hospitals, Payers, Ambulatory Care Centers, Long- Term Care Centers), Deployment Model (Private Cloud, Public Cloud, Hybrid Cloud) Players and Region - Global Market Outlook to 2026

Clinical Risk Grouping Solutions Market by XX Submarkets | Forecast Years 2022-2027 | CAGR: 13.14%  

  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
Clinical Risk Grouping Solutions are systems used to manage risk-adjusted capitation-based payment and health care management. It is used by healthcare service providers to perform daily living activities. These solutions assign each individual to a single mutually exclusive risk group which relates the historical clinical and demographic characteristics to predict future use of healthcare resources. The demand for dashboard and data visualization tools in hospitals and clinics is anticipated to boost the market growth rate in upcoming years.According to AMA, the market for Clinical Risk Grouping Solutions is expected to register a CAGR of 13.14% during the forecast period to 2026. This growth is primarily driven by Increasing Adoption of Risk Reporting Solutions By Healthcare Providers and Growing Investments In R&D Of New Therapeutics.

Globally, a noticeable market trend is evident Emergence Of Big Data Solutions. Major Players, such as 3M Corporation (United States), Optum Inc. (United States), Cerner Corporation (United States), Conduent Inc. (United States), Nuance Communications (United States), Health Catalyst (United States), HBI Solutions (United States), Johns Hopkins University (United States), Lightbeam Health Solutions (United States), Dynamic Healthcare Systems (United States), 4S Information Systems (United States), Evolent Health (United States) and Pera Health (United States) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

Key Developments in the Market:
In June 2019, Optum, Inc. acquired the DaVita Medical Group, an independent medical groups. This acquisition enables Optum to provide improved care quality and patient experiences and lower costs for 16 million people, especially for kidney care space.
In March 2019, Evolent Health entered into a joint ventureship with GlobalHealth and formed new company named True Health. The new joint venture company will focus on developing solutions for healthcare providers and payers.

Market Drivers
  • Increasing Adoption of Risk Reporting Solutions By Healthcare Providers
  • Growing Investments In R&D Of New Therapeutics

Market Trend
  • Emergence Of Big Data Solutions

Restraints
  • Lack of Infrastructure and High Cost Related to Clinical Solutions

Opportunities
Increasing Physician Burnout Due to Documentation Needs and Adoption of Artificial Intelligence (AI) and Machine Learning
Challenges
Scarcity of Skilled Healthcare IT Professionals

AMA Research follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts, but also include significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, Clinical Risk Grouping Solutions Study Sheds Light on
— The Clinical Risk Grouping Solutions Market status quo and key characteristics. To end this, Analyst at AMA organize and took survey of the Clinical Risk Grouping Solutions industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Clinical Risk Grouping Solutions industry is heading and what are the top priorities. Insights are drawn from financial analysis, the survey and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold value they currently claim, or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Type
  • Scorecard and Visualization Tools
  • Dashboard Analysis
  • Risk Report
By End Users
  • Hospitals
  • Payers
  • Ambulatory Care Centers
  • Long- Term Care Centers

By Deployment Model
  • Private Cloud
  • Public Cloud
  • Hybrid Cloud

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Adoption of Risk Reporting Solutions By Healthcare Providers
      • 3.2.2. Growing Investments In R&D Of New Therapeutics
    • 3.3. Market Challenges
      • 3.3.1. Scarcity of Skilled Healthcare IT Professionals
    • 3.4. Market Trends
      • 3.4.1. Emergence Of Big Data Solutions
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Clinical Risk Grouping Solutions, by Type, End Users , Deployment Model and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Clinical Risk Grouping Solutions (Value)
      • 5.2.1. Global Clinical Risk Grouping Solutions by: Type (Value)
        • 5.2.1.1. Scorecard and Visualization Tools
        • 5.2.1.2. Dashboard Analysis
        • 5.2.1.3. Risk Report
      • 5.2.2. Global Clinical Risk Grouping Solutions by: Deployment Model (Value)
        • 5.2.2.1. Private Cloud
        • 5.2.2.2. Public Cloud
        • 5.2.2.3. Hybrid Cloud
      • 5.2.3. Global Clinical Risk Grouping Solutions Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
  • 6. Clinical Risk Grouping Solutions: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. 3M Corporation (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Optum Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Cerner Corporation (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Conduent Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Nuance Communications (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Health Catalyst (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. HBI Solutions (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Johns Hopkins University (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Lightbeam Health Solutions (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Dynamic Healthcare Systems (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. 4S Information Systems (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Evolent Health (United States)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. Pera Health (United States)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
  • 7. Global Clinical Risk Grouping Solutions Sale, by Type, End Users , Deployment Model and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Clinical Risk Grouping Solutions (Value)
      • 7.2.1. Global Clinical Risk Grouping Solutions by: Type (Value)
        • 7.2.1.1. Scorecard and Visualization Tools
        • 7.2.1.2. Dashboard Analysis
        • 7.2.1.3. Risk Report
      • 7.2.2. Global Clinical Risk Grouping Solutions by: Deployment Model (Value)
        • 7.2.2.1. Private Cloud
        • 7.2.2.2. Public Cloud
        • 7.2.2.3. Hybrid Cloud
      • 7.2.3. Global Clinical Risk Grouping Solutions Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Clinical Risk Grouping Solutions: by Type(USD Million)
  • Table 2. Clinical Risk Grouping Solutions Scorecard and Visualization Tools , by Region USD Million (2015-2020)
  • Table 3. Clinical Risk Grouping Solutions Dashboard Analysis , by Region USD Million (2015-2020)
  • Table 4. Clinical Risk Grouping Solutions Risk Report , by Region USD Million (2015-2020)
  • Table 5. Clinical Risk Grouping Solutions: by Deployment Model(USD Million)
  • Table 6. Clinical Risk Grouping Solutions Private Cloud , by Region USD Million (2015-2020)
  • Table 7. Clinical Risk Grouping Solutions Public Cloud , by Region USD Million (2015-2020)
  • Table 8. Clinical Risk Grouping Solutions Hybrid Cloud , by Region USD Million (2015-2020)
  • Table 9. South America Clinical Risk Grouping Solutions, by Country USD Million (2015-2020)
  • Table 10. South America Clinical Risk Grouping Solutions, by Type USD Million (2015-2020)
  • Table 11. South America Clinical Risk Grouping Solutions, by End Users USD Million (2015-2020)
  • Table 12. South America Clinical Risk Grouping Solutions, by Deployment Model USD Million (2015-2020)
  • Table 13. Brazil Clinical Risk Grouping Solutions, by Type USD Million (2015-2020)
  • Table 14. Brazil Clinical Risk Grouping Solutions, by End Users USD Million (2015-2020)
  • Table 15. Brazil Clinical Risk Grouping Solutions, by Deployment Model USD Million (2015-2020)
  • Table 16. Argentina Clinical Risk Grouping Solutions, by Type USD Million (2015-2020)
  • Table 17. Argentina Clinical Risk Grouping Solutions, by End Users USD Million (2015-2020)
  • Table 18. Argentina Clinical Risk Grouping Solutions, by Deployment Model USD Million (2015-2020)
  • Table 19. Rest of South America Clinical Risk Grouping Solutions, by Type USD Million (2015-2020)
  • Table 20. Rest of South America Clinical Risk Grouping Solutions, by End Users USD Million (2015-2020)
  • Table 21. Rest of South America Clinical Risk Grouping Solutions, by Deployment Model USD Million (2015-2020)
  • Table 22. Asia Pacific Clinical Risk Grouping Solutions, by Country USD Million (2015-2020)
  • Table 23. Asia Pacific Clinical Risk Grouping Solutions, by Type USD Million (2015-2020)
  • Table 24. Asia Pacific Clinical Risk Grouping Solutions, by End Users USD Million (2015-2020)
  • Table 25. Asia Pacific Clinical Risk Grouping Solutions, by Deployment Model USD Million (2015-2020)
  • Table 26. China Clinical Risk Grouping Solutions, by Type USD Million (2015-2020)
  • Table 27. China Clinical Risk Grouping Solutions, by End Users USD Million (2015-2020)
  • Table 28. China Clinical Risk Grouping Solutions, by Deployment Model USD Million (2015-2020)
  • Table 29. Japan Clinical Risk Grouping Solutions, by Type USD Million (2015-2020)
  • Table 30. Japan Clinical Risk Grouping Solutions, by End Users USD Million (2015-2020)
  • Table 31. Japan Clinical Risk Grouping Solutions, by Deployment Model USD Million (2015-2020)
  • Table 32. India Clinical Risk Grouping Solutions, by Type USD Million (2015-2020)
  • Table 33. India Clinical Risk Grouping Solutions, by End Users USD Million (2015-2020)
  • Table 34. India Clinical Risk Grouping Solutions, by Deployment Model USD Million (2015-2020)
  • Table 35. South Korea Clinical Risk Grouping Solutions, by Type USD Million (2015-2020)
  • Table 36. South Korea Clinical Risk Grouping Solutions, by End Users USD Million (2015-2020)
  • Table 37. South Korea Clinical Risk Grouping Solutions, by Deployment Model USD Million (2015-2020)
  • Table 38. Taiwan Clinical Risk Grouping Solutions, by Type USD Million (2015-2020)
  • Table 39. Taiwan Clinical Risk Grouping Solutions, by End Users USD Million (2015-2020)
  • Table 40. Taiwan Clinical Risk Grouping Solutions, by Deployment Model USD Million (2015-2020)
  • Table 41. Australia Clinical Risk Grouping Solutions, by Type USD Million (2015-2020)
  • Table 42. Australia Clinical Risk Grouping Solutions, by End Users USD Million (2015-2020)
  • Table 43. Australia Clinical Risk Grouping Solutions, by Deployment Model USD Million (2015-2020)
  • Table 44. Rest of Asia-Pacific Clinical Risk Grouping Solutions, by Type USD Million (2015-2020)
  • Table 45. Rest of Asia-Pacific Clinical Risk Grouping Solutions, by End Users USD Million (2015-2020)
  • Table 46. Rest of Asia-Pacific Clinical Risk Grouping Solutions, by Deployment Model USD Million (2015-2020)
  • Table 47. Europe Clinical Risk Grouping Solutions, by Country USD Million (2015-2020)
  • Table 48. Europe Clinical Risk Grouping Solutions, by Type USD Million (2015-2020)
  • Table 49. Europe Clinical Risk Grouping Solutions, by End Users USD Million (2015-2020)
  • Table 50. Europe Clinical Risk Grouping Solutions, by Deployment Model USD Million (2015-2020)
  • Table 51. Germany Clinical Risk Grouping Solutions, by Type USD Million (2015-2020)
  • Table 52. Germany Clinical Risk Grouping Solutions, by End Users USD Million (2015-2020)
  • Table 53. Germany Clinical Risk Grouping Solutions, by Deployment Model USD Million (2015-2020)
  • Table 54. France Clinical Risk Grouping Solutions, by Type USD Million (2015-2020)
  • Table 55. France Clinical Risk Grouping Solutions, by End Users USD Million (2015-2020)
  • Table 56. France Clinical Risk Grouping Solutions, by Deployment Model USD Million (2015-2020)
  • Table 57. Italy Clinical Risk Grouping Solutions, by Type USD Million (2015-2020)
  • Table 58. Italy Clinical Risk Grouping Solutions, by End Users USD Million (2015-2020)
  • Table 59. Italy Clinical Risk Grouping Solutions, by Deployment Model USD Million (2015-2020)
  • Table 60. United Kingdom Clinical Risk Grouping Solutions, by Type USD Million (2015-2020)
  • Table 61. United Kingdom Clinical Risk Grouping Solutions, by End Users USD Million (2015-2020)
  • Table 62. United Kingdom Clinical Risk Grouping Solutions, by Deployment Model USD Million (2015-2020)
  • Table 63. Netherlands Clinical Risk Grouping Solutions, by Type USD Million (2015-2020)
  • Table 64. Netherlands Clinical Risk Grouping Solutions, by End Users USD Million (2015-2020)
  • Table 65. Netherlands Clinical Risk Grouping Solutions, by Deployment Model USD Million (2015-2020)
  • Table 66. Rest of Europe Clinical Risk Grouping Solutions, by Type USD Million (2015-2020)
  • Table 67. Rest of Europe Clinical Risk Grouping Solutions, by End Users USD Million (2015-2020)
  • Table 68. Rest of Europe Clinical Risk Grouping Solutions, by Deployment Model USD Million (2015-2020)
  • Table 69. MEA Clinical Risk Grouping Solutions, by Country USD Million (2015-2020)
  • Table 70. MEA Clinical Risk Grouping Solutions, by Type USD Million (2015-2020)
  • Table 71. MEA Clinical Risk Grouping Solutions, by End Users USD Million (2015-2020)
  • Table 72. MEA Clinical Risk Grouping Solutions, by Deployment Model USD Million (2015-2020)
  • Table 73. Middle East Clinical Risk Grouping Solutions, by Type USD Million (2015-2020)
  • Table 74. Middle East Clinical Risk Grouping Solutions, by End Users USD Million (2015-2020)
  • Table 75. Middle East Clinical Risk Grouping Solutions, by Deployment Model USD Million (2015-2020)
  • Table 76. Africa Clinical Risk Grouping Solutions, by Type USD Million (2015-2020)
  • Table 77. Africa Clinical Risk Grouping Solutions, by End Users USD Million (2015-2020)
  • Table 78. Africa Clinical Risk Grouping Solutions, by Deployment Model USD Million (2015-2020)
  • Table 79. North America Clinical Risk Grouping Solutions, by Country USD Million (2015-2020)
  • Table 80. North America Clinical Risk Grouping Solutions, by Type USD Million (2015-2020)
  • Table 81. North America Clinical Risk Grouping Solutions, by End Users USD Million (2015-2020)
  • Table 82. North America Clinical Risk Grouping Solutions, by Deployment Model USD Million (2015-2020)
  • Table 83. United States Clinical Risk Grouping Solutions, by Type USD Million (2015-2020)
  • Table 84. United States Clinical Risk Grouping Solutions, by End Users USD Million (2015-2020)
  • Table 85. United States Clinical Risk Grouping Solutions, by Deployment Model USD Million (2015-2020)
  • Table 86. Canada Clinical Risk Grouping Solutions, by Type USD Million (2015-2020)
  • Table 87. Canada Clinical Risk Grouping Solutions, by End Users USD Million (2015-2020)
  • Table 88. Canada Clinical Risk Grouping Solutions, by Deployment Model USD Million (2015-2020)
  • Table 89. Mexico Clinical Risk Grouping Solutions, by Type USD Million (2015-2020)
  • Table 90. Mexico Clinical Risk Grouping Solutions, by End Users USD Million (2015-2020)
  • Table 91. Mexico Clinical Risk Grouping Solutions, by Deployment Model USD Million (2015-2020)
  • Table 92. Company Basic Information, Sales Area and Its Competitors
  • Table 93. Company Basic Information, Sales Area and Its Competitors
  • Table 94. Company Basic Information, Sales Area and Its Competitors
  • Table 95. Company Basic Information, Sales Area and Its Competitors
  • Table 96. Company Basic Information, Sales Area and Its Competitors
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Clinical Risk Grouping Solutions: by Type(USD Million)
  • Table 106. Clinical Risk Grouping Solutions Scorecard and Visualization Tools , by Region USD Million (2021-2026)
  • Table 107. Clinical Risk Grouping Solutions Dashboard Analysis , by Region USD Million (2021-2026)
  • Table 108. Clinical Risk Grouping Solutions Risk Report , by Region USD Million (2021-2026)
  • Table 109. Clinical Risk Grouping Solutions: by Deployment Model(USD Million)
  • Table 110. Clinical Risk Grouping Solutions Private Cloud , by Region USD Million (2021-2026)
  • Table 111. Clinical Risk Grouping Solutions Public Cloud , by Region USD Million (2021-2026)
  • Table 112. Clinical Risk Grouping Solutions Hybrid Cloud , by Region USD Million (2021-2026)
  • Table 113. South America Clinical Risk Grouping Solutions, by Country USD Million (2021-2026)
  • Table 114. South America Clinical Risk Grouping Solutions, by Type USD Million (2021-2026)
  • Table 115. South America Clinical Risk Grouping Solutions, by End Users USD Million (2021-2026)
  • Table 116. South America Clinical Risk Grouping Solutions, by Deployment Model USD Million (2021-2026)
  • Table 117. Brazil Clinical Risk Grouping Solutions, by Type USD Million (2021-2026)
  • Table 118. Brazil Clinical Risk Grouping Solutions, by End Users USD Million (2021-2026)
  • Table 119. Brazil Clinical Risk Grouping Solutions, by Deployment Model USD Million (2021-2026)
  • Table 120. Argentina Clinical Risk Grouping Solutions, by Type USD Million (2021-2026)
  • Table 121. Argentina Clinical Risk Grouping Solutions, by End Users USD Million (2021-2026)
  • Table 122. Argentina Clinical Risk Grouping Solutions, by Deployment Model USD Million (2021-2026)
  • Table 123. Rest of South America Clinical Risk Grouping Solutions, by Type USD Million (2021-2026)
  • Table 124. Rest of South America Clinical Risk Grouping Solutions, by End Users USD Million (2021-2026)
  • Table 125. Rest of South America Clinical Risk Grouping Solutions, by Deployment Model USD Million (2021-2026)
  • Table 126. Asia Pacific Clinical Risk Grouping Solutions, by Country USD Million (2021-2026)
  • Table 127. Asia Pacific Clinical Risk Grouping Solutions, by Type USD Million (2021-2026)
  • Table 128. Asia Pacific Clinical Risk Grouping Solutions, by End Users USD Million (2021-2026)
  • Table 129. Asia Pacific Clinical Risk Grouping Solutions, by Deployment Model USD Million (2021-2026)
  • Table 130. China Clinical Risk Grouping Solutions, by Type USD Million (2021-2026)
  • Table 131. China Clinical Risk Grouping Solutions, by End Users USD Million (2021-2026)
  • Table 132. China Clinical Risk Grouping Solutions, by Deployment Model USD Million (2021-2026)
  • Table 133. Japan Clinical Risk Grouping Solutions, by Type USD Million (2021-2026)
  • Table 134. Japan Clinical Risk Grouping Solutions, by End Users USD Million (2021-2026)
  • Table 135. Japan Clinical Risk Grouping Solutions, by Deployment Model USD Million (2021-2026)
  • Table 136. India Clinical Risk Grouping Solutions, by Type USD Million (2021-2026)
  • Table 137. India Clinical Risk Grouping Solutions, by End Users USD Million (2021-2026)
  • Table 138. India Clinical Risk Grouping Solutions, by Deployment Model USD Million (2021-2026)
  • Table 139. South Korea Clinical Risk Grouping Solutions, by Type USD Million (2021-2026)
  • Table 140. South Korea Clinical Risk Grouping Solutions, by End Users USD Million (2021-2026)
  • Table 141. South Korea Clinical Risk Grouping Solutions, by Deployment Model USD Million (2021-2026)
  • Table 142. Taiwan Clinical Risk Grouping Solutions, by Type USD Million (2021-2026)
  • Table 143. Taiwan Clinical Risk Grouping Solutions, by End Users USD Million (2021-2026)
  • Table 144. Taiwan Clinical Risk Grouping Solutions, by Deployment Model USD Million (2021-2026)
  • Table 145. Australia Clinical Risk Grouping Solutions, by Type USD Million (2021-2026)
  • Table 146. Australia Clinical Risk Grouping Solutions, by End Users USD Million (2021-2026)
  • Table 147. Australia Clinical Risk Grouping Solutions, by Deployment Model USD Million (2021-2026)
  • Table 148. Rest of Asia-Pacific Clinical Risk Grouping Solutions, by Type USD Million (2021-2026)
  • Table 149. Rest of Asia-Pacific Clinical Risk Grouping Solutions, by End Users USD Million (2021-2026)
  • Table 150. Rest of Asia-Pacific Clinical Risk Grouping Solutions, by Deployment Model USD Million (2021-2026)
  • Table 151. Europe Clinical Risk Grouping Solutions, by Country USD Million (2021-2026)
  • Table 152. Europe Clinical Risk Grouping Solutions, by Type USD Million (2021-2026)
  • Table 153. Europe Clinical Risk Grouping Solutions, by End Users USD Million (2021-2026)
  • Table 154. Europe Clinical Risk Grouping Solutions, by Deployment Model USD Million (2021-2026)
  • Table 155. Germany Clinical Risk Grouping Solutions, by Type USD Million (2021-2026)
  • Table 156. Germany Clinical Risk Grouping Solutions, by End Users USD Million (2021-2026)
  • Table 157. Germany Clinical Risk Grouping Solutions, by Deployment Model USD Million (2021-2026)
  • Table 158. France Clinical Risk Grouping Solutions, by Type USD Million (2021-2026)
  • Table 159. France Clinical Risk Grouping Solutions, by End Users USD Million (2021-2026)
  • Table 160. France Clinical Risk Grouping Solutions, by Deployment Model USD Million (2021-2026)
  • Table 161. Italy Clinical Risk Grouping Solutions, by Type USD Million (2021-2026)
  • Table 162. Italy Clinical Risk Grouping Solutions, by End Users USD Million (2021-2026)
  • Table 163. Italy Clinical Risk Grouping Solutions, by Deployment Model USD Million (2021-2026)
  • Table 164. United Kingdom Clinical Risk Grouping Solutions, by Type USD Million (2021-2026)
  • Table 165. United Kingdom Clinical Risk Grouping Solutions, by End Users USD Million (2021-2026)
  • Table 166. United Kingdom Clinical Risk Grouping Solutions, by Deployment Model USD Million (2021-2026)
  • Table 167. Netherlands Clinical Risk Grouping Solutions, by Type USD Million (2021-2026)
  • Table 168. Netherlands Clinical Risk Grouping Solutions, by End Users USD Million (2021-2026)
  • Table 169. Netherlands Clinical Risk Grouping Solutions, by Deployment Model USD Million (2021-2026)
  • Table 170. Rest of Europe Clinical Risk Grouping Solutions, by Type USD Million (2021-2026)
  • Table 171. Rest of Europe Clinical Risk Grouping Solutions, by End Users USD Million (2021-2026)
  • Table 172. Rest of Europe Clinical Risk Grouping Solutions, by Deployment Model USD Million (2021-2026)
  • Table 173. MEA Clinical Risk Grouping Solutions, by Country USD Million (2021-2026)
  • Table 174. MEA Clinical Risk Grouping Solutions, by Type USD Million (2021-2026)
  • Table 175. MEA Clinical Risk Grouping Solutions, by End Users USD Million (2021-2026)
  • Table 176. MEA Clinical Risk Grouping Solutions, by Deployment Model USD Million (2021-2026)
  • Table 177. Middle East Clinical Risk Grouping Solutions, by Type USD Million (2021-2026)
  • Table 178. Middle East Clinical Risk Grouping Solutions, by End Users USD Million (2021-2026)
  • Table 179. Middle East Clinical Risk Grouping Solutions, by Deployment Model USD Million (2021-2026)
  • Table 180. Africa Clinical Risk Grouping Solutions, by Type USD Million (2021-2026)
  • Table 181. Africa Clinical Risk Grouping Solutions, by End Users USD Million (2021-2026)
  • Table 182. Africa Clinical Risk Grouping Solutions, by Deployment Model USD Million (2021-2026)
  • Table 183. North America Clinical Risk Grouping Solutions, by Country USD Million (2021-2026)
  • Table 184. North America Clinical Risk Grouping Solutions, by Type USD Million (2021-2026)
  • Table 185. North America Clinical Risk Grouping Solutions, by End Users USD Million (2021-2026)
  • Table 186. North America Clinical Risk Grouping Solutions, by Deployment Model USD Million (2021-2026)
  • Table 187. United States Clinical Risk Grouping Solutions, by Type USD Million (2021-2026)
  • Table 188. United States Clinical Risk Grouping Solutions, by End Users USD Million (2021-2026)
  • Table 189. United States Clinical Risk Grouping Solutions, by Deployment Model USD Million (2021-2026)
  • Table 190. Canada Clinical Risk Grouping Solutions, by Type USD Million (2021-2026)
  • Table 191. Canada Clinical Risk Grouping Solutions, by End Users USD Million (2021-2026)
  • Table 192. Canada Clinical Risk Grouping Solutions, by Deployment Model USD Million (2021-2026)
  • Table 193. Mexico Clinical Risk Grouping Solutions, by Type USD Million (2021-2026)
  • Table 194. Mexico Clinical Risk Grouping Solutions, by End Users USD Million (2021-2026)
  • Table 195. Mexico Clinical Risk Grouping Solutions, by Deployment Model USD Million (2021-2026)
  • Table 196. Research Programs/Design for This Report
  • Table 197. Key Data Information from Secondary Sources
  • Table 198. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Clinical Risk Grouping Solutions: by Type USD Million (2015-2020)
  • Figure 5. Global Clinical Risk Grouping Solutions: by Deployment Model USD Million (2015-2020)
  • Figure 6. South America Clinical Risk Grouping Solutions Share (%), by Country
  • Figure 7. Asia Pacific Clinical Risk Grouping Solutions Share (%), by Country
  • Figure 8. Europe Clinical Risk Grouping Solutions Share (%), by Country
  • Figure 9. MEA Clinical Risk Grouping Solutions Share (%), by Country
  • Figure 10. North America Clinical Risk Grouping Solutions Share (%), by Country
  • Figure 11. Global Clinical Risk Grouping Solutions share by Players 2020 (%)
  • Figure 12. Global Clinical Risk Grouping Solutions share by Players (Top 3) 2020(%)
  • Figure 13. Global Clinical Risk Grouping Solutions share by Players (Top 5) 2020(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. 3M Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 16. 3M Corporation (United States) Revenue: by Geography 2020
  • Figure 17. Optum Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 18. Optum Inc. (United States) Revenue: by Geography 2020
  • Figure 19. Cerner Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 20. Cerner Corporation (United States) Revenue: by Geography 2020
  • Figure 21. Conduent Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 22. Conduent Inc. (United States) Revenue: by Geography 2020
  • Figure 23. Nuance Communications (United States) Revenue, Net Income and Gross profit
  • Figure 24. Nuance Communications (United States) Revenue: by Geography 2020
  • Figure 25. Health Catalyst (United States) Revenue, Net Income and Gross profit
  • Figure 26. Health Catalyst (United States) Revenue: by Geography 2020
  • Figure 27. HBI Solutions (United States) Revenue, Net Income and Gross profit
  • Figure 28. HBI Solutions (United States) Revenue: by Geography 2020
  • Figure 29. Johns Hopkins University (United States) Revenue, Net Income and Gross profit
  • Figure 30. Johns Hopkins University (United States) Revenue: by Geography 2020
  • Figure 31. Lightbeam Health Solutions (United States) Revenue, Net Income and Gross profit
  • Figure 32. Lightbeam Health Solutions (United States) Revenue: by Geography 2020
  • Figure 33. Dynamic Healthcare Systems (United States) Revenue, Net Income and Gross profit
  • Figure 34. Dynamic Healthcare Systems (United States) Revenue: by Geography 2020
  • Figure 35. 4S Information Systems (United States) Revenue, Net Income and Gross profit
  • Figure 36. 4S Information Systems (United States) Revenue: by Geography 2020
  • Figure 37. Evolent Health (United States) Revenue, Net Income and Gross profit
  • Figure 38. Evolent Health (United States) Revenue: by Geography 2020
  • Figure 39. Pera Health (United States) Revenue, Net Income and Gross profit
  • Figure 40. Pera Health (United States) Revenue: by Geography 2020
  • Figure 41. Global Clinical Risk Grouping Solutions: by Type USD Million (2021-2026)
  • Figure 42. Global Clinical Risk Grouping Solutions: by Deployment Model USD Million (2021-2026)
  • Figure 43. South America Clinical Risk Grouping Solutions Share (%), by Country
  • Figure 44. Asia Pacific Clinical Risk Grouping Solutions Share (%), by Country
  • Figure 45. Europe Clinical Risk Grouping Solutions Share (%), by Country
  • Figure 46. MEA Clinical Risk Grouping Solutions Share (%), by Country
  • Figure 47. North America Clinical Risk Grouping Solutions Share (%), by Country
List of companies from research coverage that are profiled in the study
  • 3M Corporation (United States)
  • Optum Inc. (United States)
  • Cerner Corporation (United States)
  • Conduent Inc. (United States)
  • Nuance Communications (United States)
  • Health Catalyst (United States)
  • HBI Solutions (United States)
  • Johns Hopkins University (United States)
  • Lightbeam Health Solutions (United States)
  • Dynamic Healthcare Systems (United States)
  • 4S Information Systems (United States)
  • Evolent Health (United States)
  • Pera Health (United States)
Select User Access Type

Key Highlights of Report


Apr 2021 232 Pages 87 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Know More About Global Clinical Risk Grouping Solutions Market Report?